Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Enterprise Value (2023 - 2025)

CG Oncology filings provide 3 years of Enterprise Value readings, the most recent being -$742.2 million for Q4 2025.

  • On a quarterly basis, Enterprise Value changed 0.02% to -$742.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$742.2 million, a 0.02% change, with the full-year FY2025 number at -$742.2 million, changed 0.02% from a year prior.
  • Enterprise Value hit -$742.2 million in Q4 2025 for CG Oncology, down from -$680.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$187.7 million in Q4 2023 to a low of -$742.2 million in Q4 2025.
  • Median Enterprise Value over the past 3 years was -$661.1 million (2025), compared with a mean of -$595.7 million.
  • Biggest five-year swings in Enterprise Value: tumbled 295.37% in 2024 and later decreased 0.02% in 2025.
  • CG Oncology's Enterprise Value stood at -$187.7 million in 2023, then tumbled by 295.37% to -$742.0 million in 2024, then dropped by 0.02% to -$742.2 million in 2025.
  • The last three reported values for Enterprise Value were -$742.2 million (Q4 2025), -$680.3 million (Q3 2025), and -$661.1 million (Q2 2025) per Business Quant data.